Please use this identifier to cite or link to this item:
Title: Drugs that increase the risk of community-acquired pneumonia: a narrative review
Author: Liapikou, Adamantia
Cillóniz, Catia
Torres Martí, Antoni
Keywords: Pneumònia adquirida a la comunitat
Efectes secundaris dels medicaments
Factors de risc en les malalties
Community-acquired pneumonia
Drug side effects
Risk factors in diseases
Issue Date: Oct-2018
Publisher: Taylor and Francis
Abstract: INTRODUCTION: Community-acquired pneumonia (CAP), a major cause of morbidity and mortality, is the leading infectious cause of death in the developed world. Population-based studies and systematic reviews have identified a large number of risk factors for the development of pneumonia in adults. In addition to age, lifestyle habits, and comorbidities, some forms of pharmacotherapy may also increase the risk for CAP. AREAS COVERED: MEDLINE, CENTRAL, and Web of Science were used in 2017 to search for case-control, cohort studies, as well as randomized controlled trials and meta-analysis that involved outpatient proton pump inhibitors (PPIs), inhaled corticosteroids (ICSs), antipsychotics, oral antidiabetics, and CAP diagnosis in patients aged >18 years. EXPERT OPINION: Our review confirmed that the use of ICSs, PPIs or antipsychotic drugs was independently associated with an increased risk for CAP. We also identified a positive association between specific oral antidiabetics and the development of pneumonia.
Note: Versió postprint del document publicat a:
It is part of: Expert Opinion On Drug Safety, 2018, vol. 17, num. 10, p. 991-1003
Related resource:
ISSN: 1474-0338
Appears in Collections:Articles publicats en revistes (Medicina)
Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer)

Files in This Item:
File Description SizeFormat 
686790.pdf1.44 MBAdobe PDFView/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.